Q-omics provides the consensus-scored MIR491 profile across patient tissues and cancer cell-line models. MIR491 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MIR491 is differentially expressed in 4, with the highest sampling consensus in PAAD. Additionally, MIR491 RNA expression shows 10,976 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, PAAD, and THYM as cancer lineages where MIR491 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR491 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR491 survival associations across molecular data types. MIR491 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR491 RNA expression–survival associations across cancer types. High MIR491 expression shows unfavorable associations in UCEC, MESO, UVM and LUSC, but favorable associations in HNSC and ACC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .009). Together, the overview and detailed table identify HNSC as the clearest survival context for MIR491 RNA expression.
This table summarizes MIR491 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in PAAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR491. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR491 shows lower tumor expression in PAAD and HNSC and higher tumor expression in LUAD and COAD. The PAAD box plot shows higher MIR491 RNA expression in normal versus tumor tissue (log2 FC = −0.547, t-test p = .029).
This table shows molecular features associated with MIR491 in patient tissues and cancer cell lines. In patient samples, MIR491 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
